$8.59
Today
as of Jul 22, 16:52 ET
Last 30 days
Recent Press Releases & News
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences
Is Ocular Therapeuticx, Inc. (OCUL) Stock Positioned for Growth After Positive FDA Feedback on Axpaxli?
Overview
52-week range
$6.23
$16
23% of range
Avg surprise (last 3)
-22.4%
Avg reaction (last 2)
-6.4%
0% positive
Latest IV / EM
70%
EM ±5.0% · $9 · Jul 24
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 5, 2026 | Mar/2026 | $-0.41 | $-0.32 | -28.1% | -10.8% | -0.6% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.38 | — | — | — | — | financials |
| Tue Aug 5, 2025 | Jun/2025 | $-0.39 | $-0.35 | -11.4% | — | — | earnings |
| Mon May 5, 2025 | Mar/2025 | $-0.37 | $-0.29 | -27.6% | — | -12.2% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.22 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.26 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.49 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.25 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.26 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Aug 4, 2026 | Jun/2026 | OTHER | -$0.40 | -$0.39 | -2.6% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | $1M | — | $2M | $2M | $1M | — | $2M | $2M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-93M | — | $-69M | $-68M | $-64M | — | $-46M | $-44M |
| Net income | $-89M | — | $-69M | $-68M | $-64M | — | $-36M | $-44M |
| EPS (diluted) | $-0.40 | — | $-0.38 | $-0.39 | $-0.38 | — | $-0.22 | $-0.26 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $667M | $737M | $345M | $391M | $350M | $392M | $427M | $460M |
| Inventory | $4M | $4M | $3M | $3M | $3M | $3M | $2M | $3M |
| Total current assets | $706M | $782M | $387M | $433M | $388M | $441M | $473M | $499M |
| Total assets | $733M | $808M | $411M | $451M | $406M | $458M | $490M | $517M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $151M | $154M | $153M | $145M | $140M | $143M | $138M | $139M |
| Total equity | $582M | $654M | $258M | $306M | $266M | $315M | $352M | $378M |